Nasir Mohammed, Dejene Kefelegn, Bedru Mohammed, Markos Sura
Pediatrics and Child Health Department, Hawassa University, Hawassa, Ethiopia.
Cardiac Center Ethiopia, Addis Ababa, Ethiopia.
BMC Cardiovasc Disord. 2025 May 26;25(1):402. doi: 10.1186/s12872-025-04881-8.
Percutaneous balloon pulmonary valvuloplasty (BPV) is the preferred treatment for pulmonary valve stenosis owing to its effectiveness and safety in patients with appropriate valves. However, there is a lack of research on the immediate and midterm results in developing nations. Thus, this study aimed to evaluate the immediate and midterm outcomes of patients who underwent BPV at the Cardiac Center of Ethiopia.
A follow-up study was conducted from April 2023 to August 2023 using retrospective chart reviews and phone interviews involving 138 patients aged ≤ 18 years who underwent balloon BPV for moderate to severe pulmonary stenosis (defined as peak pulmonary valvular gradient ≥ 50 mmHg) at the Cardiac Center of Ethiopia between January 2012 and March 2023. The study's primary objective was to assess the procedure's immediate success and mid-term outcomes. The study employed various statistical tests, including a multivariable logistic regression model, to identify predictors of the development of moderate to severe pulmonary regurgitation and restenosis.
The patients' median age was 3.95 years (1.5-13 years), with a female to male ratio 1.6. Following BPV, there was a significant decrease in the median peak pulmonary trans-valvular gradient from 106 mmHg to 40 mmHg (p < 0.001). The immediate success rate was 71%, with post-procedural complications at 4.3%. In a median follow-up of 114 months (IQR 72-132 months), 34.1% developed moderate to severe PR, and restenosis occurred in 24.4%. High balloon annulus ratio predicted moderate to severe PR, while dysplastic or complex pulmonary valve, high pre-procedural and immediate post-procedural peak gradients, and high pre-procedural left ventricular systolic pressure predicted restenosis.
Most patients typically achieve initial success following BPV at our center. However, it is not unusual for moderate to severe pulmonary regurgitation and restenosis to develop during follow-up. As such, this study underscores the significance of thorough follow-up care for patients who underwent BPV to promptly detect and address potential complications.
经皮球囊肺动脉瓣成形术(BPV)因其对合适瓣膜患者的有效性和安全性,是肺动脉瓣狭窄的首选治疗方法。然而,发展中国家在其近期和中期结果方面缺乏研究。因此,本研究旨在评估在埃塞俄比亚心脏中心接受BPV治疗患者的近期和中期结果。
2023年4月至2023年8月进行了一项随访研究,采用回顾性病历审查和电话访谈,涉及138例年龄≤18岁的患者,这些患者于2012年1月至2023年3月在埃塞俄比亚心脏中心因中度至重度肺动脉狭窄(定义为肺动脉瓣峰值压差≥50 mmHg)接受了球囊BPV治疗。该研究的主要目的是评估该手术的近期成功率和中期结果。该研究采用了各种统计测试,包括多变量逻辑回归模型,以确定中度至重度肺动脉反流和再狭窄发生的预测因素。
患者的中位年龄为3.95岁(1.5 - 13岁),女性与男性比例为1.6。BPV术后,肺动脉跨瓣峰值压差中位数从106 mmHg显著降至40 mmHg(p < 0.001)。近期成功率为71%,术后并发症发生率为4.3%。中位随访114个月(四分位间距72 - 132个月)时,34.1%的患者出现中度至重度PR,24.4%的患者发生再狭窄。高球囊瓣环比可预测中度至重度PR,而发育异常或复杂的肺动脉瓣、术前和术后即刻的高峰值压差以及术前高左心室收缩压可预测再狭窄。
在我们中心,大多数患者在BPV术后通常能取得初步成功。然而,随访期间出现中度至重度肺动脉反流和再狭窄并不罕见。因此,本研究强调了对接受BPV治疗的患者进行全面随访护理的重要性,以便及时发现并处理潜在并发症。